ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 405 - 405, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 520 - 520, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 895 - 896, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'MAINTENANCE OLAPARIB FOR BRCA-MUTATED OVARIAN CANCER (OC) PATIENTS IN 1ST LINE AND PLATINUM-SENSITIVE RELAPSED (PSR) SETTINGS: MAXIMIZING TREATMENT OPPORTUNITIES', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 29, pp. A133 - A133, http://dx.doi.org/10.1136/ijgc-2019-IGCS.321
,2019, 'Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5501
,2019, 'Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5539
,2019, 'Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5551
,2019, 'How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5549
,2019, 'Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5541
,2019, 'Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT084
,2018, 'EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 21, pp. S73 - S73, http://dx.doi.org/10.1016/j.jval.2018.09.429
,2018, 'From development to implementation: The Australian experience of oncofertility decision aids', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 44 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Genitourinary and sexual health after breast cancer: The role of breast care nurses in providing support and care', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 184 - 185, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii340, http://dx.doi.org/10.1093/annonc/mdy285.158
,2018, 'When will i feel normal again? Exploring the trajectories and predictors of patient-reported outcomes after completion of primary therapy for ovarian cancer', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, WA, Seattle, Vol. 25, pp. 112 - 112, presented at 12th Rivkin-Centre Biennial Ovarian Cancer Research Symposium, WA, Seattle, 13 September 2018 - 15 September 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000497337700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'A Phase 1 Trial of Olaparib and Oral Metronomic. Cyclophosphamide in Patients with Metastatic BRCA-Associated Breast/Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer/High Grade Serous Ovarian Cancers', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 58 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, Vol. 41, pp. 88 - 89, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424914300235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1942 - 1943, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1941 - 1941, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Mucinous Ovarian Cancers of Uncertain Primary (MO-CUP) - Does the Site of Origin Really Matter?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 73 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 300 MG TABLETS BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088
,2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087
,2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'CURRENT CARE AND NEEDS OF ADULT CANCER SURVIVORS - A CROSS-SECTIONAL SURVEY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 8, pp. 356 - 357, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'OVER (Olive oil Vaginal Exercises and Replens) come', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, Vol. 15, pp. S332 - S332, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000242413901224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2003, 'A randomised trial of a decision aid for women at risk for ovarian cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, Vol. 12, pp. S107 - S107, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.c.6547304.v1
,2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.c.6547304
,2023, Supplementary Data 1 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533917.v1
,2023, Supplementary Data 1 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533917
,2023, Supplementary Data 2 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533914.v1
,2023, Supplementary Data 2 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533914
,2023, Supplementary Data 3 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533911.v1
,2023, Supplementary Data 3 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533911
,2023, Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533908
,2023, Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533908.v1
,2023, Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.c.6532782
,2023, Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.c.6532782.v1
,2023, Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488654
,2023, Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488654.v1
,2023, Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488651.v1
,2023, Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488651
,2023, Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488645.v1
,2023, Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, , http://dx.doi.org/10.1158/1078-0432.22488645
,